Author Archive

Drug Patent Expirations for Apr 30, 2015

DrugPatentWatch provides competitive intelligence on small-molecule drugs and the 90,000 global patents covering them Click the patents below for more details, or visit DrugPatentWatch.com for more options. LAMISIL (terbinafine) Novartis Patent number: 5,681,849 Expiration Date: Apr 28, 2015 LAMISIL AT (terbinafine hydrochloride) Novartis Patent number: 5,681,849 Expiration Date: Apr 28, 2015 LAMISIL AT (terbinafine) Novartis […]


Cancer’s Science Revolution Comes on Little Cat Feet

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. Back when I wrote ISO A Scientific Revolution in Cancer Research in April of 2013, I truly did not expect to be able to greet the revolution by […]


Drug Patent Expirations for Apr 9, 2015

DrugPatentWatch provides competitive intelligence on small-molecule drugs and the 90,000 global patents covering them Click the patents below for more details, or visit DrugPatentWatch.com for more options. NUVIGIL (armodafinil) Cephalon Patent number: RE 37,516 Expiration Date: Apr 6, 2015 PROVIGIL (modafinil) Cephalon Patent number: RE 37,516 Expiration Date: Apr 6, 2015 FLOVENT HFA (fluticasone propionate) […]


Journal of Commercial Biotechnology New Issue Published

Journal of Commercial Biotechnology Labels, Lawyers, & Logic Peter J. Pitts America deserves access to high-quality health care without avoidable medical errors and complications. This achievable goal begins with harnessing and using the power of information. And that begins with clear, accurate, and usable labeling.The American health care system is undermined, underserved, and undervalued when […]


Expand Your Cell-Based Protein Manufacturing with Hollow Fiber Bioreactors

This is a guest post from Halina Zakowicz, Marketing Specialist at Biovest International, Inc. Do you have a response to Halina’s post? Respond in the comments section below. Scaling up cell culture production can be a tricky proposition. Generating large amounts of cell-secreted proteins is labor-intensive when utilizing traditional cell culture methods. Quality and yields […]


Social Network Analysis of Pharmaceutical Innovation

I was just notified of a fascinating paper citing my research from DrugPatentWatch.com. Briefly, I found two surprising results: Firstly, pharmaceutical innovation has been essentially immobile — it remains almost completely rooted in the United States and Western Europe. Secondly, there is virtually no innovation coming out of so-called emerging economies such as India and China (i.e. <1% as […]


Biotechnology in Countries Starting with “I” – Part 7: India

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. For the next chapter in this continuing series, let’s turn back to India and the draft National IPR Policy currently under debate in New Delhi. A great deal […]


New CMS Guidance for Biotech Industry On Coverage With Evidence Development: It’s All About The Outcomes

This is a guest post from Robert E. Wanerman, a member of Epstein Becker Green’s Health Care and Life Sciences practice. Do you have a response to Robert’s post? Respond in the comments section below. For many biotech manufacturers, obtaining Medicare coverage is a significant milestone in commercializing an item or service. Although Medicare coverage […]


New Years Bio-Pharmaceutical Resolution To Nurture MSME Innovation

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. At the start of a bright and shiny new year in 2015, I am thinking about my own New Years resolutions as well as one that I would […]


PatentDrop.com posts public-domain inventions

Patents require regular ‘maintenance’ payments to keep them in force. Because the cost of maintaining large patent portfolios can be substantial, many companies elect to abandon patents that they feel are not worth pursuing. Sometimes these patents are abandoned because they are outside a company’s focus, and in other cases they may represent markets too small for […]